Direct Comparison of Autologous and Allogeneic Transplantation of iPSC-Derived Neural Cells in the Brain of a Nonhuman Primate

Asuka Morizane,1 Daisuke Doi,1 Tetsuhiro Kikuchi,1 Keisuke Okita,1 Akitsu Hotta,1,2,3 Toshiyuki Kawasaki,4 Takuya Hayashi,2 Hirotaka Onoe,4 Takashi Shiina,6 Shinya Yamanaka,1 and Jun Takahashi1,7,8,*

1Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan
2PRESTO, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan
3Institute for Integrated Cell–Material Sciences (iCeMS), Kyoto University, Kyoto 606-8501, Japan
4Bio-function Imaging Team, RIKEN Center for Life Science Technologies (RIKEN CLST), Kobe 650-0047, Japan
5Functional Architecture Imaging Unit, RIKEN Center for Life Science Technologies (RIKEN CLST), Kobe 650-0047, Japan
6Department of Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, Isehara 259-1143, Japan
7Department of Biological Repair, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
8Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
*Correspondence: jbtaka@cira.kyoto-u.ac.jp
http://dx.doi.org/10.1016/j.stemcr.2013.08.007
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

SUMMARY

Induced pluripotent stem cells (iPSCs) provide the potential for autologous transplantation using cells derived from a patient’s own cells. However, the immunogenicity of iPSCs or their derivatives has been a matter of controversy, and up to now there has been no direct comparison of autologous and allogeneic transplantation in the brains of humans or nonhuman primates. Here, using nonhuman primates, we found that the autologous transplantation of iPSC-derived neurons elicited only a minimal immune response in the brain. In contrast, the allografts caused an acquired immune response with the activation of microglia (IBA-1+/MHC class II+) and the infiltration of leukocytes (CD45+/CD3+). Consequently, a higher number of dopaminergic neurons survived in the autografts. Our results suggest that the autologous transplantation of iPSC-derived neural cells is advantageous for minimizing the immune response in the brain compared with allogeneic grafts.

INTRODUCTION

In recent studies, murine induced pluripotent stem cell (iPSC)-derived teratomas in the subcutaneous space induced an immune response in syngeneic mice (Zhao et al., 2011). In contrast, syngeneic transplantation of skin and bone marrow tissues (Araki et al., 2013) or endothelial, hepatic, and neuronal cells (Guha et al., 2013) derived from iPSCs showed a limited or no immune response, respectively. These rodent studies investigated the immunogenicity of teratomas, chimeric mouse-derived tissues, or ectopic grafts, but did not convincingly simulate the clinical situation.

Parkinson’s disease is one of the most promising targets for cell therapy with pluripotent stem cells. In which differentiated dopaminergic (DA) neurons are transplanted into the putamen of a patient’s brain (Lindvall and Björklund, 2011). In order to assess the immunogenicity of iPSC-derived neural cells in a primate brain, we generated iPSCs from four cynomolgus monkeys and directly compared the autologous and allogeneic transplantation of iPSC-derived neural cells.

RESULTS

iPSCs Derived from Nonhuman Primates Differentiate into DA Neurons

For the first two animals (Nos. 1 and 4), we established iPSCs from fibroblasts derived from the oral mucosa using retroviral vectors (Okita et al., 2011). For the other two animals (Nos. 6 and 8), we used peripheral blood mononuclear cells (PBMCs) with nonintegrating episomal vectors (Okita et al., 2013). We selected the best clone from each animal according to the following criteria: a stable embryonic stem cell (ESC)-like morphology of the colonies after passaging, expression of pluripotent markers, few or no integrated transgenes (Figures 1A–1F; Figure S1 available online), and the potential for stable neural differentiation. A PCR analysis revealed that all of the clones with retroviral vectors showed apparent expression of remaining transgenes (Figures S1C and S1D), whereas the clones with episomal vectors never did (Figure S1F). To detect the iPSC-derived cells in a brain, we introduced GFP (Figures 1G and 1H). The selected clones of iPSCs had the potential to generate teratomas in the testes of a severe combined immunodeficiency (SCID) mouse within 12 weeks (Figures 1I–1M).

To efficiently generate DA neurons from monkey iPSCs, we modified previously described protocols (Eiraku et al., 2008; Chambers et al., 2012; Morizane et al., 2011). Briefly, dissociated iPSCs were incubated in ultralow-attachment 96-well plates in medium containing inhibitors of bone morphogenetic protein (BMP) and Activin/NODAL signaling to initiate neural induction. To induce differentiation of the cells toward midbrain DA neurons, purmorphamine/FGF8 and FGF2/FGF20 were added sequentially...
During differentiation, the expression of a pluripotent marker (OCT4) gradually decreased, whereas the levels of neural and DA markers increased (Figures 1O and 1P). The differentiated neurons expressed markers characteristic of midbrain DA neurons (LMX1A, FOXA2, TH, and PITX3; Figures 1Q and 1R). Besides DA neurons,
other types of neurons, such as serotonergic and GABAergic neurons, as well as proliferating neural progenitors positive for Ki67, were also observed as minor populations (Figures 1Q and 1R). OCT4 was not detected by immunocytochemistry or flow cytometry in the differentiation culture even from the retroviral iPSCs (Figure 1O).

Expression of Major Histocompatibility Complex by Monkey iPSCs In Vitro

Next, we investigated the expression of major histocompatibility complex I (MHC-I) in iPSC-derived neural cells. Flow cytometry using antibodies against human leukocyte antigen (HLA)-A, HLA-B, and HLA-C revealed that mature neurons on days 35 and 71 expressed only a low level of MHC-I, and that the expression was enhanced in response to interferon gamma (IFN-\(\gamma\); 25 ng/ml for 48 hr; Figure 2A). The expression level of the mRNAs was approximately 1:100 compared with peripheral blood cells in both fibroblast- and blood-cell-derived iPSCs, which was again increased by exposure to IFN-\(\gamma\) (Figure 2B). These results suggest that donor-derived neurons could express MHC-I when IFN-\(\gamma\) was secreted by the host brain under inflammatory conditions.

To ensure that the MHC-I of the host animal and donor cells were mismatched in the allotransplantation cases, we performed genotyping of the expressed MHCs from the monkeys, which were purpose-bred, second-generation (F2), captive-born animals. As shown in Figures 2C and 2E, and Table S1, each monkey expressed different MHCs in terms of the A and B alleles. Based on these results, we chose the most mismatched combination for allotransplantation (Figures 2D and 2E).

Autografts Elicit Only a Minimal Immune Response in the Primate Brain

We injected the iPSC-derived neural cells (day 28) into the original monkey as an autograft, and into the MHC-mismatched monkey as an allograft (Figure 2D). Each animal received six separate injections (~8.0 \(\times\) 10^5 cells in a 4 \(\mu\)l suspension per tract) in the left striatum, and was observed for 3.5–4 months without immunosuppression. In the brain, both brain-resident microglia and circulating immune cells work as key players in immunological responses. Once the microglia are activated, they develop antigen-presenting activity. PK11195 selectively binds to the translocator protein that is expressed on activated microglia (Shah et al., 1994; Vowinckel et al., 1997). Therefore, positron emission tomography (PET) studies with [\(^{11}\)C]PK11195 have been used to visualize brain inflammation in patients (Debruyne et al., 2003).

In sequential PET studies, we observed increased uptake of [\(^{11}\)C]PK11195 in one allograft (animal No. 10) at 3 months (Figures 3A and 3B). We could not detect any apparent uptake in the other animals or at any other time points (Figure S2). Intriguingly, the serum level of IFN-\(\gamma\) temporarily increased at 2 months after the transplant in three animals (Figure 3C). An immunofluorescence study conducted at 3.5–4 months showed that MHC-II* cells were more frequently found in allografts than in autografts, especially in the monkey with increased uptake of [\(^{11}\)C]PK11195 (Figure 3D, No. 10). The MHC-II staining never overlapped with that of GFP of the donor cells (Figure 3F), whereas it generally overlapped with that of IBA1 (Figure 3G), indicating that MHC-II was expressed by host-derived microglia. Consistently, the number and density of IBA1* cells were higher in allografts than in autografts (Figures 3E, 3H, and S4C). An increase in the expression of MHC might trigger the recruitment of circulating immune cells, including T cells. An immunofluorescence study revealed that more CD45* cells (a marker for pan-leukocytes) accumulated in allografts compared with autografts (Figures 3I and 3J). Most of the CD45* cells were CD3* T cells, and 60% of them were CD8* killer T cells (Figures 3K and 3L). These findings suggest that an acquired immune response was elicited only in the allografts in the primate brain.

DA Neurons Survive in Both Types of Grafts, but a Higher Number Are Observed in Autografts

In order to evaluate the survival of the grafted cells, we performed MRI scanning and a histological analysis at 3–4 months posttransplantation (Figure 4). Hematoxylin and eosin (H&E) staining and immunostaining for GFP of the brain slices demonstrated that the grafted cells survived in both auto- and allotransplantation without immunosuppression (Figures 4A–4F). Furthermore, there were no significant differences in volume between the auto- and allotransplantation (Figure 4K). Immunostaining for tyrosine hydroxylase (TH), a marker for DA neurons, revealed that a large number of DA neurons (4,428 ± 1,130 per tract, n = 22) survived in the autografts (Figures 4G, 4H, 4L, and 4M). The surviving DA neurons coexpressed the markers of a mesencephalic phenotype, such as FOXA2, NURR1, and the dopamine transporter (DAT) (Figures 4N–4P). Even in allografts without immunosuppression, the TH* neurons survived well (2,247 ± 641 per tract, n = 22), but the number and density were lower than in autografts (Figures 4I, 4J, 4L, and 4M). We also found a small number of astrocytes (GFP*/GFAP*), as well as mature neurons (GFP*/NEUN*), in vivo (Figure S4B).

DISCUSSION

In this study, we induced DA neurons from monkey iPSCs by directed differentiation in vitro, and demonstrated that
Figure 2. Identification of MHC Expression and Typing of Donor Cells

(A) Flow-cytometric analyses for MHC-I (HLA-A, HLA-B, and HLA-C). Incubation of the cells with IFN-γ for 48 hr increased the MHC-I expression (green).

(legend continued on next page)
autologous transplantation of the iPSC-derived cells elicited only a minimal immune response in the nonhuman primate brain. Previous reports have suggested that either autologous grafts of iPSC-derived neural cells (Emborg et al., 2013; Maria et al., 2013) or allogeneic grafts of fetal ventral mesencephalic cells (Redmond et al., 2008) can survive in a primate brain without immunosuppression. None of these studies, however, directly compared the immunogenicity of autologous grafts with that of allogeneic ones. Our results clearly show differences in both immunogenicity and cell survival between these two types of grafts, and support the idea that immunosuppression is not necessary for autologous transplantation of iPSC-derived neural cells into the brain. The [11C]PK11195 PET study was useful for real-time visualization of this phenomenon. Furthermore, this technique can also be applied to patients in the clinical setting, which would help to determine when and if immunosuppressive drugs can be withdrawn.

Although we did not examine acute immune responses or inflammation within 48 hr, it is noteworthy that the responses were observed 2 or 3 months posttransplantation. In the case of iPSC-based transplantation, there are four possible mechanisms that can cause inflammatory and immune responses: (1) direct allore cognition of mismatched MHC or minor antigens of the donor cells, (2) indirect allore cognition through host-derived antigen-presenting cells, (3) expression of fetal antigens due to immature stem cells or remaining transgenes, and (4) mechanical damage rather than MHC mismatch. Because of the low expression level of MHC-I by the donor cells, direct allore cognition is unlikely to be the main cause. However, donor-cell-derived astrocytes (Figure S4B), which can express both MHC-I and MHC-II to recruit T cells in response to IFN-γ, may have contributed to the direct reaction in the late stage. Considering the high expression level of MHC-II by host-derived microglia in the allografts (Figures 3D–3G), indirect allore cognition seems to have played a major role in the present study. This requires the internalization and processing of the alloantigens, which are then recognized in peptidic form bound to recipient MHC-II molecules, possibly accounting for the late onset of the immune response.

Autografts derived from iPSCs generated by retroviral vectors resulted in the accumulation of larger numbers of IBA1+ and CD45+ cells compared with those generated using episcopal vectors, probably due to the residual expression of the transgenes (Figure S3). This indicates that residual transgenes can be immunogenic, and that it is therefore critical to use integration-free iPSCs. Mechanical damage caused by needle trauma can also activate host astrocytes and microglia to secrete proinflammatory cytokines, which recruit leukocytes. Consistently, we found IBA1+ cells along the needle tract in the animals that received control injections (Figures 3E and S4C), but this was limited to a small area and not likely to play a major role.

Another important finding is that, in spite of the immune responses mounted by the host brain, a substantial number of TH+ cells survived in the allografts. This is consistent with previous clinical reports of human fetal cell transplantation. Postmortem analyses of the patients revealed robust survival of DA neurons in spite of the fact that numerous immune cells were present around the graft (Kordower et al., 1997). In two double-blind clinical trials, immunosuppressive drugs were never used (Freed et al., 2001) or were withdrawn after 6 months (Olanow et al., 2003). In these cases, the cells from multiple fetuses were used without HLA matching, but more than 50,000 TH+ cells had survived after several years. Our quantitative PCR (qPCR) study in vitro showed that the expression of MHC-I increased in response to IFN-γ, but the expression level was still 1/10 that of untreated monkey peripheral blood cells (Figure 2B). The in vivo studies revealed that the serum level of IFN-γ increased at 2 months, and CD45+ cells (including CD8+ cells) accumulated in the allografts 3.5–4 months after the transplant. On the other hand, the levels of INF-γ in the cerebrospinal fluid (CSF) and the levels of tumor necrosis factor α (TNF-α) in both the serum and CSF were below the limit of detection by ELISA (data not shown). An immunofluorescence study did not reveal any apparent expression of MHC-I by the grafted cells (Figure S4A). Therefore, it is possible that the immune response in the primate brain was not strong enough to reject all of the donor cells. These findings

(B) Temporal MHC-I expression analysis of monkey iPSCs by qPCR. The data were obtained from three (n = 3 for fibro iPSCs) or five (n = 5 for blood iPSCs) different experiments. Data are shown as the means ± SD.

(C and E) Monkey MHC-I (Mafa) allele sequences detected by next-generation sequencing (C) and cluster analysis of the monkey MHCs (E). The colored letters indicate a comparatively high expression level of the MHC-I allele, comprising >10% of cDNA sequence reads. The gray background indicates the MHC-A allele, and the others indicate the MHC-B allele.

(D) Combinations of donor cells and recipient animals. Episomal v., established with episomal vectors; P, passage number just before starting the differentiation of donor cells; Retro v., established with retrovirus vectors.

See also Figure S4D and Tables S1–S3.
Immunogenicity of iPSC-Derived Neurons in Primates

A

PK11195 PET

B

PK11195

C

IFN-γ in Serum

D

MHC class II

Autograft

Allograft

Donor No. 1

No. 1

No. 2

Donor No. 4

No. 4

No. 3

Donor No. 6

No. 6

No. 10

Donor No. 8

No. 8

No. 9

No. 8, HE ref.

E

IBA-1

Autograft

Allograft

Donor No. 6

No. 6

No. 10

Donor No. 8

No. 8

No. 9

F

GFP MHC-Ⅱ

G

MHC-Ⅱ IBA-1

H

IBA-1

Cells / Tract

Cells / mm³

I

CD45

Autograft

Allograft

Donor No. 1

No. 1

No. 2

Donor No. 4

No. 4

No. 3

Donor No. 6

No. 6

No. 10

Donor No. 8

No. 8

No. 9

J

CD45

Cells / Tract

Cells / mm³

K

CD45

CD3

merge

L

CD8 CD3

(legend on next page)
closely correlate with the results of previous murine experiments (Hudson et al., 1994; Shinoda et al., 1995). To apply our findings to a more clinically relevant setting, we investigated the expression of HLA-I during neural differentiation of human ESCs (hESCs) and iPSCs by qPCR (Figure S4D). The expression level was 1/100 compared with that of human peripheral blood cells in both hESCs and iPSCs, and it was similarly elevated in response to IFN-γ. It is difficult to precisely compare immunogenicity in monkeys with that in humans, but the low expression level of MHC-I by the donor cells may account for the mild rejection in both monkey and human neural transplantation.

Our results indicate that autologous transplantation is beneficial in terms of the immune response and cell survival. However, this strategy is associated with higher costs and labor. An alternative method is allogeneic transplantation using HLA-matched iPSC stocks (Okita et al., 2011). PBMCs were transfected with a combination of plasmid vectors (OCT3/4, SOX2, KLF4, L-MYC, and LIN28) as described previously (Okita et al., 2013). The primate iPSCs were maintained on mouse embryonic fibroblast feeders treated with mitomycin-C (Sigma-Aldrich). They were differentiated into DA neurons through the SFEbq method (Eiraku et al., 2008) with dual SMAD inhibitors (Chambers et al., 2012; Morizane et al., 2011; Figure 1N). The cells were transplanted on day 28 of differentiation. For in vitro analysis, the cells were dissociated with Accumax (Innovative Cell Technologies) on day 28 and cultured on eight-well glass chamber slides coated with poly-l-ornithine and laminin for an additional 11 days (for a total of 39 days).

Genotyping of MHC
MHC genotypes were assigned by comparing the sequences with known MHC allele sequences released from the Immuno Polymorphism Database (http://www.ebi.ac.uk/ipd/index.html). See also Supplemental Experimental Procedures.

Immunostaining and Histological Analyses
For in vivo studies, the fixed frozen brains were sliced at 40 μm thickness and immunologically stained via the free-floating method. The primary antibodies used are listed in Table S3. See also Supplemental Experimental Procedures.

MRI and PET Studies
PET scans with [11C]PK11195 were performed with the use of an animal PET scanner (microPET Focus220; Siemens Medical Solutions) to identify the activation of microglia. High-resolution T1-weighted and T2-weighted images were obtained using a 3T MRI scanner (MAGNETOM Verio; Siemens AG) to identify the injection site of grafts in the postero-dorsal striatum and to evaluate graft survival. See also Supplemental Experimental Procedures.

Transplantation
Floating aggregates (day 28) were harvested and dissociated into small clumps of 20–30 cells with Accumax. The cells were suspended in the last culture medium (Figure 1N), which was
Figure 4. Graft Survival in a Primate Brain

(A–P) Histological analyses of a brain section with H&E staining, and the immunohistochemical findings. (K) Quantitative analyses of the graft volume. (L and M) Survival of TH⁺ neurons in the grafts. (N and O) The TH⁺ neurons expressed markers of the midbrain phenotype: Foxa2 (N) and Nurr1 (O). (P) The DAT was also positively stained.

(legend continued on next page)
neurobasal medium with B27 with added ascorbic acid, dibutyryl-cAMP, gliocell-line-derived neurotrophic factor, and brain-derived neurotrophic factor. We also added a ROCK inhibitor, Y27632, to increase the survival of the donor cells. The suspension was prepared at a concentration of 2 × 10⁵ cells/μL and 4 μL of the suspension was injected through a 22-gauge needle with a Hamilton syringe. We made six (two coronal × three sagittal) tracts of injection in one side of the putamen. In total, 4.8 × 10⁶ cells per animal (8.0 × 10⁵ cells/tract × 6 tracts) were injected into one side of the putamen according to the coordinate decided by the MRI image of each monkey. The same volume of the culture medium was injected to the contralateral side as control. No immunosuppressant was used. Under deep anesthesia, the animals were sacrificed and perfused transcardially with 4% paraformaldehyde after 3.5–4 months of observation.

Statistics

The data were expressed as the mean ± SD or mean ± SEM, and differences were tested by commercially available software Prism 6 (GraphPad). With regard to the histological data for the auto- and allo-tracts, after confirming normal distribution, we proceeded to perform statistical analyses with ratio paired t tests. Some tracts were omitted from the assessment because of technical problems; p values < 0.05 were considered to be significant.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, four figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2013.08.007.

ACKNOWLEDGMENTS

We thank Ms. E. Yamasaki and Mr. K. Kubota for their technical assistance, Drs. K. Tanaka and T. Sato for the genetic analyses, Dr. Y. Yamada for his valuable advice on the histological studies, Dr. Y. Ono for providing antibodies, and Dr. H. Kawamoto for his critical advice on the manuscript. This study was supported by grants from the Highway Project for Realization of Regenerative Medicine (Ministry of Education, Culture, Sports, Science and Technology), the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program, Japan Society for the Promotion of Science), and the Shimizu Foundation for Immunology and Neuroscience Grant for 2012.

REFERENCES

Akesson, E., Wolmer-Solberg, N., Cederarv, M., Falci, S., and Odedberg, J. (2009). Human neural stem cells and astrocytes, but not neurons, suppress an allogeneic lymphocyte response. Stem Cell Res. (Amst.) 2, 56–67.

Araki, R., Uda, M., Hoki, Y., Sunayama, M., Nakamura, M., Ando, S., Sugitua, M., Ideno, H., Shimada, A., Nifuji, A., and Abe, M. (2013). Negligible immunogenecity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494, 100–104.

Chambers, S.M., Qi, Y., Mica, Y., Lee, G., Zhang, X.J., Niu, L., Bilsland, J., Cao, L., Stevens, E., Whiting, P., et al. (2012). Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715–720.

Chastain, E.M., Duncan, D.S., Rodgers, J.M., and Miller, S.D. (2011). The role of antigen presenting cells in multiple sclerosis. Biochim. Biophys. Acta 1812, 265–274.

Debruyne, J.C., Versijpt, J., Van Laere, K.J., De Vos, E., Keppens, J., Strickmans, K., Achten, E., Slegers, G., Diercks, R.A., Korf, J., and De Reuck, J.L. (2003). PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur. J. Neurol. 10, 257–264.

Deleidi, M., Hargus, G., Hallett, P., Osborn, T., and Isacson, O. (2011). Development of histocompatible primed-induced pluripotent stem cells for neural transplantation. Stem Cells 29, 1052–1063.

Eiraku, M., Watanabe, K., Matsuo-Takasaki, M., Kawada, M., Yonemura, S., Matsumura, M., Wataya, T., Nishiyama, A., Muguruma, K., and Sasai, Y. (2008). Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 3, 519–532.

Emborg, M.E., Liu, Y., Xi, J., Zhang, X., Yin, Y., Lu, J., Joers, V., Swanson, C., Holden, J.E., and Zhang, S.C. (2013). Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep. 3, 646–650.

Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowskii, J.Q., et al. (2001). Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med. 344, 710–719.

Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P., and Boyd, A.S. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12, 407–412.

Hudson, J.L., Hoffman, A., Strömborg, I., Hoffer, B.J., and Moorhead, J.W. (1994). Allogeneic grafts of fetal dopamine neurons, suppress an allogeneic lymphocyte response. Stem Cell Res. (Amst.) 2, 56–67.

(Q–S) Magnetic resonance images of a representative animal (No. 6, autograft) at 3 months after the transplant. The arrowheads indicate the directions of the cell injections. (Q) coronal, (R) axial, and (S) sagittal. The letter L indicates the left side. Scale bars: 2 mm (A, B, D, F, H, and J), 50 μm (C, E, G, I, N, O, and P), and 1 cm (Q–S). Quantitative data are presented as the mean ± SEM (n = 22 tracts). Ratio paired t tests were performed for the auto- and allo-tracts: **p = 0.0021 (L), **p = 0.0088 (M). See also Figure S4 and Table S3.
Kordower, J.H., Styren, S., Clarke, M., DeKosky, S.T., Olanow, C.W., and Freeman, T.B. (1997). Fetal grafting for Parkinson’s disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 6, 213–219.

Lindvall, O., and Björklund, A. (2011). Cell therapeutics in Parkinson’s disease. Neurotherapeutics 8, 539–548.

Maria, S., Helle, B., Tristan, L., Gaynor, S., Arnar, A., Michele, M., Teresia, O., Oliver, C., Roger, S., et al. (2013). Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31, 1548–1562.

Morizane, A., Doi, D., Kikuchi, T., Nishimura, K., and Takahashi, J. (2011). Small-molecule inhibitors of bone morphogenetic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J. Neurosci. Res. 89, 117–126.

Nakatsuji, N., Nakajima, F., and Tokunaga, K. (2008). HLA-haplotype banking and iPSC cells. Nat. Biotechnol. 26, 739–740.

Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPSC cells. Nat. Methods 8, 409–412.

Okita, K., Yamakawa, T., Matsumura, Y., Sato, Y., Amano, N., Watanabe, A., Goshima, N., and Yamanaka, S. (2013). An efficient nonviral method to generate integration-free human induced pluripotent cells from cord blood and peripheral blood cells. Stem Cells 31, 458–466.

Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.E., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, J., and Freeman, T.B. (2003). A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol. 54, 403–414.

Redmond, D.E., Jr., Vinuela, A., Kordower, J.H., and Isacson, O. (2008). Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease. Neurobiol. Dis. 29, 103–116.

Shah, F., Hume, S.P., Pike, V.W., Ashworth, S., and McDermott, J. (1994). Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl. Med. Biol. 21, 573–581.

Shinoda, M., Hudson, J.L., Strömberg, I., Hoffer, B.J., Moorhead, J.W., and Olson, L. (1995). Allogeneic grafts of fetal dopamine neurons: immunological reactions following active and adoptive immunizations. Brain Res. 680, 180–195.

Vowinckel, E., Reutens, D., Becher, B., Verge, G., Evans, A., Owens, T., and Antel, J.P. (1997). PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 50, 345–353.

Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature 474, 212–215.